These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22482240)

  • 1. [Which HbA1c and lipid targets in patients with type 2 diabetes?].
    Paquot N; Scheen AJ
    Rev Med Liege; 2012 Feb; 67(2):98-103. PubMed ID: 22482240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
    Bergenstal RM; Li Y; Porter TK; Weaver C; Han J
    Diabetes Obes Metab; 2013 Mar; 15(3):264-71. PubMed ID: 23078638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
    Meier M; Hummel M
    Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetes.
    Camara S; Bouenizabila E; Hermans MP; Ahn SA; Rousseau MF
    Diabetes Metab Syndr; 2014; 8(3):145-51. PubMed ID: 25220917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
    Ferdinand KC
    J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
    Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
    Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
    Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
    Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Blood glucose control and cardiovascular disease in patients with type 2 diabetes. Results of ACCORD, ADVANCE and VA-Diabetes trials].
    Radermecker RP; Philips JC; Jandrain B; Paquot N; Scheen AJ
    Rev Med Liege; 2008; 63(7-8):511-8. PubMed ID: 18771232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
    Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: Report from the Swedish National Diabetes Register.
    Eeg-Olofsson K; Zethelius B; Gudbjörnsdottir S; Eliasson B; Svensson AM; Cederholm J
    Diab Vasc Dis Res; 2016 Jul; 13(4):268-77. PubMed ID: 27190080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia.
    Khan HA; Sobki SH; Khan SA
    Clin Exp Med; 2007 Mar; 7(1):24-9. PubMed ID: 17380302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
    Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
    Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus.
    Artha IMJR; Bhargah A; Dharmawan NK; Pande UW; Triyana KA; Mahariski PA; Yuwono J; Bhargah V; Prabawa IPY; Manuaba IBAP; Rina IK
    Vasc Health Risk Manag; 2019; 15():149-157. PubMed ID: 31239693
    [No Abstract]   [Full Text] [Related]  

  • 17. Factors Associated with Poor Glycemic and Lipid Levels in Ambulatory Diabetes Mellitus Type 2 Patients in Asmara, Eritrea: A Cross-Sectional Study.
    Achila OO; Ghebretinsae M; Kidane A; Simon M; Makonen S; Rezene Y
    J Diabetes Res; 2020; 2020():5901569. PubMed ID: 32090121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes.
    Calanna S; Scicali R; Di Pino A; Knop FK; Piro S; Rabuazzo AM; Purrello F
    Nutr Metab Cardiovasc Dis; 2014 Jun; 24(6):670-6. PubMed ID: 24656139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous behavior of lipids according to HbA1c levels undermines the plausibility of metabolic syndrome in type 1 diabetes: data from a nationwide multicenter survey.
    Giuffrida FM; Guedes AD; Rocco ER; Mory DB; Dualib P; Matos OS; Chaves-Fonseca RM; Cobas RA; Negrato CA; Gomes MB; Dib SA;
    Cardiovasc Diabetol; 2012 Dec; 11():156. PubMed ID: 23270560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing diabetes care regarding cardiovascular targets at general practice level: Direct@GP.
    Wens J; Gerard R; Vandenberghe H
    Prim Care Diabetes; 2011 Apr; 5(1):19-24. PubMed ID: 21030327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.